Search

Your search keyword '"Kilari D"' showing total 19 results
Start Over Author "Kilari D" Publisher elsevier b.v.
19 results on '"Kilari D"'

5. 1696P A phase I/ II trial of pazopanib (Paz) alternating (alt) with bevacizumab (Bev) in treatment-naïve metastatic clear cell renal cell carcinoma (mccRCC) patients (pts): Phase II results.

Author

George, S., Vaishampayan, U.N., Hutson, A., Groman, A., Roche, C.L., Herbst, L., Kallicharsn-Smith, R., DiRaddo, A-M., Farrell, E., Kilari, D., Gopalakrishnan, D., Heath, E., Wulff-Burchfield, E., Appleman, L.J., and Parikh, R.

Subjects
*RENAL cell carcinoma, *BEVACIZUMAB, *METASTASIS
Published
2024
Full Text
View/download PDF

6. Dose Escalated Pelvic Lymph Node Intensity Modulated Radiation Therapy (IMRT) with a Simultaneous Hypofractionated Boost to the Prostate for NCCN Very-High Risk Adenocarcinoma of the Prostate, a Prospective Phase II Clinical Trial (NCT02177292).

Author

Hall, W.A., Chunara, F., Banerjee, A., Bedi, M., Kilari, D., Bylow, K.A., Burfeind, J., Currey, A.D., Jacobsohn, K., Nelson, A., Johnson, S., Longo, J.M., Straza, M.W., and Lawton, C.A.F.

Subjects
*CLINICAL trials, *ANDROGEN deprivation therapy, *KARNOFSKY Performance Status, *GLEASON grading system, *LYMPH nodes, *PROSTATE cancer
Abstract

There remains limited data as to the efficacy of higher doses of elective radiation therapy (RT) to the pelvic lymph nodes for men with very high risk, non-metastatic adenocarcinoma of the prostate. We conducted a prospective phase II study to evaluate the toxicity and efficacy of external beam dose escalation to the pelvic lymph nodes using a simultaneous integrated boost (SIB) to the prostate. We report the long-term clinical outcomes of a prospective phase II clinical trial (NCT02177292) with a median follow up of over 10 years. Patients were eligible with biopsy proven adenocarcinoma of the prostate, a probability of lymph node risk of at least 25%, Karnofsky Performance Scale of at least 70, and no evidence of M1 disease. Acute and late toxicity were prospectively collected at each follow up using CTCAE version 4.0. Pelvic lymph nodes were treated to a dose of 56 Gy over 28 fractions with a simultaneous integrated boost (SIB) to the prostate to a total dose of 70 Gy over 28 fractions using IMRT. Patients were followed every three months for the first two years, every 6 months from years three to five, and annually. All patients received neoadjuvant, concurrent, and adjuvant androgen deprivation therapy for a median of 24 months. Secondary to the time frame of the study accrual, PSMA pet was not available. Descriptive statistics, including mean and inter-quartile ranges for all continuous variables, such as age and PSA and frequencies for all categorical variables were computed. Survival statistics were computed using the Kaplan Meier method. 80 patients were prospectively enrolled with 78 patients deemed eligible after final review. The mean patient age at biopsy was 72 (57-86), mean pre-treatment PSA was 19.01 (2.6-111.5), median T stage was T2c (T1c-T3b), 69.2% (54/78) patients had a Gleason score of 9, 28% had a Gleason score of 8. 84% of patients were classified as NCCN very high risk. At a median follow up of 10.6 years biochemical control was achieved in 92.5% of patients, distant metastasis free survival was 96.2%. Cumulative rates of all grade 2 or higher late toxicity (attributable and non-attributable to RT) was 38%, the majority of patients (62%) had grade 1 or lower toxicity. Nodal RT dose escalation in a modern prospective cohort of NCCN very high-risk prostate cancer resulted in extremely promising 10-year clinical outcomes. Radiation dose intensification to the pelvic nodes warrants further study and consideration for further testing in randomized phase III clinical trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

7. 1972P Pre-treatment (Tx) risk factors for enfortumab vedotin-induced peripheral neuropathy (EVIPN) in patients (pts) with advanced urothelial carcinoma (aUC): Analysis of UNITE.

Author

Nizam, A., Zhang, L., Jiang, C.Y., Nguyen, C.B., Bakaloudi, D.R., Bilen, M.A., Coelho Barata, P.M., Zakharia, Y., Milowsky, M.I., Kilari, D., Hoimes, C.J., Khaki, A.R., Emamekhoo, H., Gupta, S., Grivas, P., Bellmunt, J., Alva, A.S., Campbell, M.T., Alhalabi, O., and Koshkin, V.S.

Subjects
*TRANSITIONAL cell carcinoma, *PERIPHERAL neuropathy
Published
2024
Full Text
View/download PDF

9. 1643P Impact of PTEN alterations on clinical outcomes in patients (pts) with de novo metastatic prostate cancer (mPC).

Author

Thapa, B., Henderson, N., Tagawa, S.T., Hwang, C., Sokolova, A.O., Bilen, M.A., Coelho Barata, P.M., Nguyen, C.B., Tripathi, A., Ayanambakkam, A., Graham, L.S., Zakharia, Y., Koshkin, V.S., Heath, E., Dorff, T.B., Armstrong, A.J., McKay, R.R., Alva, A.S., Schweizer, M., and Kilari, D.

Subjects
*METASTASIS, *PROSTATE cancer, *TREATMENT effectiveness
Published
2024
Full Text
View/download PDF

10. Safety and Feasibility Of Dose Escalated Pelvic Lymph Node Intensity Modulated Radiation Therapy (IMRT) with a Simultaneous Hypofractionated Boost to the Prostate For High Risk Adenocarcinoma of the Prostate, a Prospective Phase II Clinical Trial.

Author

Hall, W.A., Bedi, M., Kilari, D., Bylow, K.A., Burfeind, J., Currey, A.D., See, W.A., Straza, M.W., and Lawton, C.A.F.

Subjects
*LYMPH nodes, *PROSTATE, *RADIOTHERAPY, *CLINICAL trials, *PROGRESSION-free survival
Published
2019
Full Text
View/download PDF

11. 1815P Emergent circulating tumor DNA (ctDNA) variants and ctDNA burden dynamics with potential associations with talazoparib antitumor activity in TALAPRO-1.

Author

Castro, E., Laird, D., Dorff, T., Zhao, S., van Oort, I.M., Gasparro, D., Calabro', F., Pignata, S., Geczi, L., Barthelemy, P., Kilari, D., Hopkins, J.F., Chen, H-C., Healy, C.G., Chelliserry, J., Scagliotti, G., de Bono, J.S., Mehra, N., and Fizazi, K.

Subjects
*CIRCULATING tumor DNA, *ANTINEOPLASTIC agents
Published
2023
Full Text
View/download PDF

14. 1368P TALAPRO-1: Talazoparib monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) – Exploration of tumor genetics associated with prolonged benefit.

Author

de Bono, J.S., Castro Marcos, E., Laird, D.A., Fizazi, K., Dorff, T., Zhao, S., van Oort, I.M., Gasparro, D., Calabrò, F., Pignata, S., Geczi, L., Barthelemy, P., Kilari, D., Hopkins, J.F., Chen, H-C., Healy, C.G., Chelliserry, J., Scagliotti, G.V., and Mehra, N.

Subjects
*CASTRATION-resistant prostate cancer, *DNA damage, TUMOR genetics
Published
2022
Full Text
View/download PDF

15. Concurrent Durvalumab And Radiation Therapy (DUART) followed by Adjuvant Durvalumab in Patients with Localized Urothelial Cancer of Bladder: BTCRC-GU15-023.

Author

Joshi, M., Zakharia, Y., Kaag, M., Kilari, D., Holder, S., Emamekhoo, H., Sankin, A., Liao, J., Merrill, S., DeGraff, D., Zheng, H., Warrick, J., Hauke, R., Gartrell, B., Stein, M., Drabick, J., and Tuanquin, L.C.

Subjects
*TRANSITIONAL cell carcinoma, *BLADDER cancer, *RADIOTHERAPY, *ONCOLOGISTS
Published
2020
Full Text
View/download PDF

16. 623P KEYNOTE-199 phase II study of pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update.

Author

Omlin, A.G., Graff, J.N., Hoimes, C.J., Tagawa, S.T., Hwang, C., Kilari, D., Ten Tije, A.J., McDermott, R., Vaishampayan, U.N., Elliott, T., Gerritsen, W.R., Wu, H., Kim, J., Schloss, C., de Bono, J.S., and Antonarakis, E.S.

Subjects
*CASTRATION-resistant prostate cancer, *PEMBROLIZUMAB
Published
2020
Full Text
View/download PDF

17. 227P Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199.

Author

Vaishampayan, U.N., Elliott, T., Omlin, A.G., Graff, J.N., Hoimes, C.J., Tagawa, S.T., Hwang, C., Kilari, D., Tije, A.J. Ten, McDermott, R.S., Gerritsen, W.R., Wu, H., Kim, J., Schloss, C., de Bono, J.S., and Antonarakis, E.S.

Subjects
*PEMBROLIZUMAB, *CASTRATION-resistant prostate cancer, *PROSTATE cancer treatment
Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results